Sigyn Therapeutics
Developer of extracorporeal, dialysis-like medical device technologies intended to reduce circulating inflammatory molecules and atherogenic lipoproteins for cardiovascular disease and to optimize delivery or reduce toxicity of cancer therapies via extracorporeal circuits. The company emphasizes integration with existing dialysis-machine infrastructure and is advancing first-in-human and early clinical strategies while engaging in licensing and partnership activities.
Industries
Nr. of Employees
small (1-50)
Sigyn Therapeutics
San Diego, California, United States
Products
CardioDialysis
A dialysis-like blood-purification medical technology designed to reduce circulating inflammatory molecules and cholesterol-transporting lipoproteins to address cardiovascular disease and lower incidence of major adverse cardiovascular events.
ImmunePrep platform
Extracorporeal platform designed to immobilize therapeutic antibodies in a circuit to remove circulating antibody decoys prior to antibody infusion, with the goal of improving targeted delivery of immunotherapeutic antibodies.
ChemoPrep
Extracorporeal approach to reduce circulating tumor-derived exosomes prior to chemotherapy administration to improve delivery to tumor targets and potentially allow lower dosing.
ChemoPure
Extracorporeal technology intended to extract residual off-target chemotherapy from the bloodstream after administration to reduce systemic toxicity.
CardioDialysis™
Sigyn CardioDialysis™ is a first-in-industry medical technology to treat cardiovascular disease by reducing inflammatory molecules and cholesterol-transporting lipoproteins that contribute to major adverse cardiovascular events (MACE). It is designed to be integrated during regular dialysis treatments for end-stage renal disease (ESRD) patients.
Sigyn CardioDialysis(TM)
A first-in-industry medical device to treat cardiovascular disease by reducing inflammatory molecules and cholesterol-transporting lipoproteins that contribute to major adverse cardiovascular events (MACE).
CardioDialysis
A dialysis-like blood-purification medical technology designed to reduce circulating inflammatory molecules and cholesterol-transporting lipoproteins to address cardiovascular disease and lower incidence of major adverse cardiovascular events.
ImmunePrep platform
Extracorporeal platform designed to immobilize therapeutic antibodies in a circuit to remove circulating antibody decoys prior to antibody infusion, with the goal of improving targeted delivery of immunotherapeutic antibodies.
ChemoPrep
Extracorporeal approach to reduce circulating tumor-derived exosomes prior to chemotherapy administration to improve delivery to tumor targets and potentially allow lower dosing.
ChemoPure
Extracorporeal technology intended to extract residual off-target chemotherapy from the bloodstream after administration to reduce systemic toxicity.
CardioDialysis™
Sigyn CardioDialysis™ is a first-in-industry medical technology to treat cardiovascular disease by reducing inflammatory molecules and cholesterol-transporting lipoproteins that contribute to major adverse cardiovascular events (MACE). It is designed to be integrated during regular dialysis treatments for end-stage renal disease (ESRD) patients.
Sigyn CardioDialysis(TM)
A first-in-industry medical device to treat cardiovascular disease by reducing inflammatory molecules and cholesterol-transporting lipoproteins that contribute to major adverse cardiovascular events (MACE).
Expertise Areas
- Extracorporeal blood purification
- Dialysis-device integration
- Cardiovascular device development
- Adjunctive oncology device technologies
Key Technologies
- Extracorporeal circulation systems
- Apheresis/adsorption cartridges
- Antibody immobilization within extracorporeal circuits
- Exosome capture/filtration
News & Updates
Letter of intent for licensing of the CardioDialysis technology to target traumatic brain injury-induced systemic inflammation.
Company initiative to evaluate emerging medical technologies in former NFL players at risk of chronic traumatic encephalopathy (CTE).
Company press release describing CardioDialysis as a next-generation approach to reduce MACE by removing pathogenic lipoproteins and inflammatory mediators.
Press release noting external scientific coverage that supports the rationale for blood-purification approaches in neuroinflammatory conditions.
Participation in investor and industry conferences and presentations describing the company's clinical strategy and technologies (examples include LD Micro Main Event XIX and Emerging Growth Conference).
Letter of intent for licensing of the CardioDialysis technology to target traumatic brain injury-induced systemic inflammation.
Company initiative to evaluate emerging medical technologies in former NFL players at risk of chronic traumatic encephalopathy (CTE).
Company press release describing CardioDialysis as a next-generation approach to reduce MACE by removing pathogenic lipoproteins and inflammatory mediators.
Press release noting external scientific coverage that supports the rationale for blood-purification approaches in neuroinflammatory conditions.
Participation in investor and industry conferences and presentations describing the company's clinical strategy and technologies (examples include LD Micro Main Event XIX and Emerging Growth Conference).